TSPAN18 Facilitates Bone Metastasis of Prostate Cancer by Protecting STIM1 from TRIM32-Mediated Ubiquitination

Zhou, Qianghua; Chen, Xu; Yao, Kai; Zhang, Yan Jie; He, Huixin; Hao, Hongxun; Chen, Hao; Peng, Shengmeng; Huang, Ming; Liu, Cheng; Zhang, Qiang; Xie, Ruihui; Li, Kaiwen; Lin, Tianxin; Huang, Hai

doi:10.2139/ssrn.4284630

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IHC was carried out according to the description of our previous study. 24 Formalin-fixed prostate cancer (PCa) tissue sections, numbering 40, were first hydrated using an ascending alcohol gradient. These sections then underwent antigen retrieval in a Tris-EDTA buffer, subjected to microwave treatment for a duration of 10 min.…”

Section: Immunohistochemistry (Ihc) and H-score Assessmentmentioning

confidence: 99%

MT1G, an emerging ferroptosis‐related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer

Cheng,

Lai,

Huang

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

BackgroundProstate cancer is a leading cause of cancer‐related deaths in men worldwide. Despite advances in treatment strategies, there is still a need for novel therapeutic targets and approaches. Ferroptosis has emerged as a critical process in the development and progression of several cancers, including prostate cancer (PCA). In this study, we investigate the role of MT1G, a gene implicated in immune responses and ferroptosis, in the pathogenesis of PCA. Our objective is to elucidate its prognostic significance and its impact on the tumor microenvironment, while exploring its potential in enhancing the sensitivity to immune checkpoint inhibitor (ICI) therapy.MethodsWe utilized a combination of in silico analysis and experimental techniques to investigate the role of MT1G in PCA. First, we analyzed large‐scale genomic datasets to assess the expression pattern and prognostic significance of MT1G in PCA patients. Subsequently, we performed functional assays to explore the impact of MT1G in PCA and its potential involvement in modulating immune responses. In addition, we conducted in vivo experiments to evaluate the effect of MT1G on tumor growth and response to ICI therapy.ResultsOur analysis revealed that MT1G expression is significantly downregulated in PCA tissues compared to normal prostate tissues and is associated with poor prognosis. Furthermore, MT1G overexpression inhibited the growth of PCA cells in vitro and in vivo. Importantly, we found that MT1G regulates the tumor microenvironment by modulating immune cell infiltration and inhibiting immunosuppressive factors. Furthermore, our study reveals a significant correlation between MT1G expression levels and the response to immune checkpoint inhibitor (ICI) therapy in prostate cancer (PCA) patients, as MT1G upregulation leads to an increase in PDL‐1 expression. These findings underscore the potential of MT1G as a promising predictive biomarker for ICI therapy response in PCA patients.ConclusionOur study elucidates the pivotal role played by MT1G in the pathogenesis of prostate cancer (PCA) and its profound implications for prognosis. Moreover, it raises the intriguing possibility that MT1G could pave the way for novel therapeutic approaches in PCA treatment. This potential arises from its ability to orchestrate immune infiltration within the tumor microenvironment, consequently enhancing sensitivity to immune checkpoint inhibitor (ICI) therapy. Therefore, our findings hold substantial promise for advancing our comprehension of PCA and exploring innovative therapeutic strategies.

show abstract

Section: Immunohistochemistry (Ihc) and H-score Assessmentmentioning

confidence: 99%